For CFOs & RCM leadersHIDALGA TECHNOLOGIES

Protect margin.
Measure the cost of payer friction .

Specialty drug authorizations are the largest source of avoidable revenue loss - visible delay, rework, denials, & reimbursement risk. HaloPA gives finance & rev cycle leaders payer-level visibility & workflow intelligence to identify where intervention can protect margin & accelerate access.

Financial control

Know what is affecting cash.

01
$2.1M+
Avg denial revenue protected
per clinic / year
02
7.6→2.6%
Denial rate
after 90d integrated workflows
03
4.2→2.8
Authorization days
median business days after redesign
04
9.2x+
ROI in year one
across cohort
Where financial value comes from

Turn payer friction into financial intelligence.

Measure authorization performance before relying on assumptions about denials, staffing, or cash impact.

01

Prevent avoidable denials

Identify missing evidence, payer requirements, & documentation gaps earlier, before they create downstream denial and rework.

02

Find the long-tail cases

Average turnaround hides cases that consume weeks. Surface delayed authorizations before they become exceptions no one is watching.

03

Measure payer performance

Compare turnaround, denials, peer-to-peers, & escalation patterns by payer, plan, provider, and regimen.

04

Stop low-value rework

See repeated denials, resubmissions, & escalation activity so teams can intervene instead of spending labor on the same unresolved problem.

05

Quantify administrative cost

Measure staff time across preparation, follow-up, appeals, & peer-to-peers to identify where automation produces the greatest return.

06

Connect PA to cash

Link authorization activity with your own A/R & reimbursement data to determine where payer friction is actually affecting financial performance.

Ready when you are

Run the numbers live.

Try the calculator or book a 15-minute demo with your CFO.

Book a Call